08:00 , Nov 3, 2014 |  BC Week In Review  |  Financial News

Advent Venture Partners financial update

The firm's active portfolio includes antifungal company F2G Ltd. (Manchester, U.K.), diagnostics play Biocartis S.A.(Lausanne, Switzerland), and growth hormone play Versartis Inc. (NASDAQ:VSAR, Redwood City, Calif.), which raised $144.9 million in a...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Fresh fund, same plan

Advent Venture Partners plans to stick with its long-standing investment strategy for its second dedicated life sciences fund, Advent Life Sciences Fund II, which the firm closed last week with £145.5 million ($234.3 million). "The investment...
03:01 , Oct 28, 2014 |  BC Extra  |  Financial News

Advent closes new fund with L145.5M

European VC firm Advent Venture Partners closed Advent Life Sciences Fund II with L145.5 million ($234.3 million). The fund came from new and existing LPs, including funds-of-funds, pension funds and family offices. Advent, which raised...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Agenus, 4-Antibody deal

Agenus will acquire antibody company 4-Antibody for $10 million up front in Agenus stock plus additional contingent payments, payable in cash or stock, that may exceed $40 million. Agenus will gain 4-Antibody's antibody discovery technology...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Financial News

Versartis completes venture financing

Versartis Inc., Redwood City, Calif.   Business: Endocrine/Metabolic   Date completed: 10/8/13   Type: Venture financing   Raised: $20 million   Investors: Sofinnova Ventures; Advent Venture Partners; Aisling Capital; Amunix Operating Inc.; Index Ventures; New Leaf Venture Partners   ...
00:31 , Oct 9, 2013 |  BC Extra  |  Financial News

Versartis raises $20 million in D round

Versartis Inc. (Redwood City, Calif.) raised $20 million in a series D round led by new investor Sofinnova Ventures. Existing investors Advent Venture Partners; Aisling Capital; drug delivery company Amunix Operating Inc. (Mountain View, Calif.);...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

CoCo Therapeutics neurology news

CoCo Therapeutics debuted earlier this month with undisclosed funding from Advent Venture Partners to develop retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's disease. Founding Chairman Raj Parekh, general partner at Advent, said...
07:00 , Mar 11, 2013 |  BioCentury  |  Finance

Advent warms CoCo

Advent warms CoCo On the heels of data published last month from the lab of Jonathan Corcoran, Advent Venture Partners launched CoCo Therapeutics Ltd. to develop his retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's...
01:54 , Mar 9, 2013 |  BC Extra  |  Company News

CoCo debuts to develop AD therapeutics

CoCo Therapeutics Ltd. (Oxford, U.K) debuted with undisclosed funding from Advent Venture Partners to develop retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's disease. Founding Chairman Raj Parekh, general partner at Advent, said CoCo...